UnitedHealth Group (UNH)

UnitedHealth Group has been hit with a series of bad news lately.

Shares of medical device company Artivion (NYSE:AORT) jumped 3% in the morning session after investment firm Stifel raised its price target on the stock to $36 from $30, while maintaining a Buy rating. The adjustment followed Stifel's conversations with six physicians who utilized Artivion's aortic arch dissection repair stent (AMDS) after its FDA approval. The doctors reportedly offered positive commentary about the device, noting it simplified a complex procedure and enhanced results over existing treatments. This feedback reinforced Stifel's optimistic view on the technology's launch and its potential within what the firm estimated was a $150 million US market.

Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 4.4% in the afternoon session after the company reported mixed second-quarter financial results, where a massive net loss overshadowed a revenue beat and raised guidance. The contract research organization posted revenues of $710.3 million, which exceeded analysts' expectations. However, investors focused on a staggering GAAP net loss of $374.9 million for the quarter. This loss resulted primarily from a non-cash goodwill impairment charge of $309.1 million. A goodwill impairment is an accounting adjustment made when the value of a company's assets declined. Fortrea attributed this charge to its own falling share price and market-driven interest rate increases. Further concerns arose from a weak book-to-bill ratio of 0.79x, which indicated the company secured less new business than it billed during the period.

Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) jumped 9.5% in the afternoon session after the company reported better-than-expected second-quarter financial results and raised its full-year outlook. The medical device maker reported second-quarter earnings per share of $0.60 on revenue of $64.2 million, which beat Wall Street's expectations. The company's sales jumped 15% from the previous year, pushed by higher prices and a 7% increase in the number of products sold. Strong international sales for its Artegraft product also contributed to the growth. Looking ahead, LeMaitre lifted its full-year 2025 revenue forecast to $251 million and increased its earnings guidance, signaling management's confidence in continued strong performance.

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 36.4% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year revenue forecast. The genetic testing firm announced revenue of $213.1 million, which sailed past analyst estimates of around $202 million. It also posted an adjusted profit of $0.05 per share, a significant turnaround from the minor loss that experts had predicted. A key driver for this outperformance was the company's hereditary cancer testing business, which grew 9% compared to the previous year. Bolstered by this momentum, Myriad Genetics lifted its full-year revenue guidance to a range of $818 million to $828 million and secured a new $200 million credit facility to fund its growth.

Shares of health insurance company Clover Health (NASDAQ:CLOV) fell 20.3% in the afternoon session after the company reported mixed second-quarter results where rising medical costs and a wider-than-expected loss overshadowed strong revenue growth. The technology-focused insurer announced revenue of $477.6 million, which climbed past analyst forecasts, fueled by a 32% jump in Medicare Advantage membership. However, the company posted a net loss of $0.02 per share, a reversal from a profit in the same quarter last year and a miss on analyst expectations. Investors focused on the increase in the Insurance Benefits Expense Ratio (BER), a key metric showing the portion of premiums spent on medical care, which rose to 88.4%. Compounding the issue, Clover Health also raised its forecast for the full-year BER, signaling that these higher costs would likely persist. In response to the report, analysts at UBS cut their price target on the stock.

Investors are interested in this company trading near its 52-week low.

Investors will not want to miss this update from the management team.

Between battered industries and overlooked opportunities, plenty of dividend-paying companies have slipped.

While monthly jobs reports often grab headlines, savvy investors are increasingly looking beyond employment figures to a broader array of economic indicators for a more nuanced understanding of market health. Two such crucial metrics, Personal Consumption Expenditures (PCE) inflation and the Chicago Purchasing Managers' Index (PMI), are currently providing critical

Shares of medical lens company STAAR Surgical (NASDAQ:STAA) jumped 45.6% in the afternoon session after eye-care company Alcon announced a definitive agreement to acquire the company in an all-cash deal valued at approximately $1.5 billion. Under the terms of the deal, Alcon paid $28 in cash for each share of STAAR Surgical. This price marked a 51% premium to the company's closing stock price on the previous day. STAAR Surgical manufactured implantable lenses for vision correction, including its EVO family of Implantable Collamer® Lenses. The acquisition allowed Alcon to absorb a key player in the ophthalmic surgery space.

Shares of healthcare services provider AdaptHealth Corp. (NASDAQ:AHCO) jumped 8.2% in the afternoon session after the company announced it secured a five-year exclusive agreement to become the sole provider of home medical equipment for a major national healthcare system. Under the agreement, AdaptHealth became the exclusive provider of home medical equipment and supplies for the system’s network of over 10 million members. The deal was structured primarily as a capitation payment model, a system where a provider receives a set fee per patient, which covered a mix of Medicare, Medicaid, and privately insured individuals. This significant contract news appeared to overshadow the company's second-quarter financial results, which were also released. The earnings report showed a decline in both net income and revenue compared to the same period last year, but investors seemingly prioritized the long-term growth prospects offered by the major partnership over the recent dip in financial performance.

Concerns are mounting among financial analysts that the U.S. stock market may be entering an "overheated" phase, with equity valuations reaching levels that some deem unsustainable. This apprehension comes as major indices continue to flirt with record highs, prompting a critical debate about the market's current trajectory and its

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.

The company's full-year numbers are going to be even worse than analysts expected.

Shares of healthcare services company Agilon Health (NYSE:AGL) fell 51.6% in the morning session after the company reported dismal second-quarter financial results, announced the departure of its CEO, and withdrew its full-year guidance. 

Shares of medical technology company Inspire Medical Systems (NYSE:INSP) fell 41.3% in the afternoon session after the company slashed its full-year revenue and profit forecasts, a move that overshadowed a second-quarter earnings beat. 

Shares of medical products company UFP Technologies (NASDAQ:UFPT) jumped 11.9% in the afternoon session after the company posted record second-quarter results and beat analyst profit expectations. The medical products company reported a 37.2% surge in sales to $151.2 million compared to the same period last year. Its adjusted earnings per share reached $2.50, which surpassed Wall Street's consensus estimate of $2.25. This strong performance was primarily driven by a 46% jump in its MedTech business, fueled by demand in areas like robotic-assisted surgery. However, the results included a 20% decline in its Advanced Components division, and the company noted increased labor costs pressured margins.

The healthcare giant is planning to increase prices significantly next year.

This is another case of a broken stock but not a broken business.

Shares of scientific instrument company Bruker (NASDAQ:BRKR). fell 7.4% in the afternoon session after the company reported disappointing second-quarter results and lowered its full-year financial forecast, citing challenging market demand. 

UnitedHealth has been hit hard, but its fundamentals suggest a market overreaction. Its AI-driven subsidiary Optum Insight is a hidden gem.

Dave Ramsey explains Medicare and Medicaid, highlighting differences and eligibility. Trump launches health tracking system with tech support.